{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"85.1"},{"groupId":"OG001","value":"88.2"}]}],"title":"Participants with AE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"22.4"},{"groupId":"OG001","value":"14.7"}]}],"title":"Participants with SAE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"34.3"},{"groupId":"OG001","value":"38.2"}]}],"title":"Participants with Corticosteroid (CS)-Related AE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.5"},{"groupId":"OG001","value":"7.4"}]}],"title":"Participants with CS-Related AE Grade 3 or higher"}],"denoms":[{"counts":[{"groupId":"OG000","value":"67"},{"groupId":"OG001","value":"68"}],"units":"Participants"}],"description":"An adverse event is any untoward medical occurrence in a participant to whom a medicinal product is administered and which does not necessarily have a causal relationship with this treatment. A serious adverse event is an adverse event that results in death or is life-threatening or requires/prolongs hospitalization or results in persistent/significant disability/incapacity or congenital abnormality/birth defect. Adverse events of Grade 3 of higher are severe and life-threatening adverse events CS-related adverse events - causality as determined by the investigator.","groups":[{"description":"Participants received rituximab by IV infusion on Days 1 and 15 with repeat administration on Days 168 and 182 provided specific safety criteria had been met. Participants also received MMF matching placebo orally twice daily (every 12 hours, Q12H) from Day 1 to Week 52.","id":"OG000","title":"Rituximab (RTX)"},{"description":"Participants received Mycophenolate Mofetil (MMF) orally twice daily (every 12 hours, Q12H) from Day 1 to Week 52. Participants also received rituximab matching placebo by intravenous (IV) infusion on Days 1 and 15 with repeat administration on Days 168 and 182 provided specific safety criteria had been met.","id":"OG001","title":"Mycophenolate Mofetil (MMF)"}],"paramType":"NUMBER","populationDescription":"The safety population included all participants who were randomized and received any part of an infusion of study drug or oral administration of study drug.","reportingStatus":"POSTED","timeFrame":"Baseline up to 52 Weeks (up to CCOD of 28 November 2018)","title":"Percentage of Participants With Adverse Events, Serious Adverse Events, and Corticosteroid-Related Adverse Events","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}